3/9/2010

ImmunoGen's cancer drug candidate IMGN901 received orphan-drug designation from U.S. and European regulators. The company is seeking to market the treatment for Merkel cell carcinoma, a form of skin cancer.

Full Story:
Google

Related Summaries